After a meteoric rise that saw venture capital funding for women’s health startups reach record-breaking heights in 2024, the sector is currently navigating a period of sharp contraction and strategic soul-searching. A comprehensive new report from Silicon Valley Bank (SVB), a division of First Citizens Bank, reveals a sobering reality: funding for companies focused on female-centric therapeutics, medical devices, and health technologies plummeted from $3.2 billion in 2024 to approximately $2 billion in 2025.
This decline is not merely a statistical anomaly but a reflection of a broader, systemic shift within the healthcare investment ecosystem. As capital becomes more discerning and the "hype cycle" surrounding niche markets cools, entrepreneurs are finding that the old rules of fundraising no longer apply. To survive, the women’s health sector is undergoing a profound transformation—redefining its value proposition, pivoting its marketing strategies, and attempting to prove that the path to profitability is paved with more than just good intentions.
The Landscape: A Statistical Retrenchment
The data provided by SVB paints a picture of a sector in the midst of a "reset." Beyond the headline decline in total investment, the composition of deals has shifted dramatically. The share of healthcare venture deals involving women’s health startups fell from 7.4% in 2024 to 5.7% in 2025.
Perhaps most concerning for the long-term pipeline of innovation is the cooling of interest in biopharma startups. Venture funding in this specific high-risk, high-reward segment plunged from $1.3 billion to $610 million. This steep drop-off highlights a clear investor preference for de-risked, established entities rather than the speculative, early-stage research that characterized the exuberance of the previous year.
A Chronology of the Shift
- 2024: The Peak: Fueled by post-pandemic optimism and a heightened focus on health equity, capital flooded into the sector, setting an all-time high of $3.2 billion.
- Early 2025: The Correction: As interest rates remained elevated and the "broad-market" healthcare strategy shifted toward caution, investors began demanding higher proof-of-concept thresholds.
- Mid-to-Late 2025: The Strategic Pivot: Startups began moving away from "women’s health" as a standalone silo, rebranding their technologies to emphasize broader applicability to both sexes, particularly in chronic disease management.
- 2026: The Era of "Doing More with Less": Despite a dip in overall VC volume, the market saw a surprising uptick in IPO activity (14 public offerings in 2025 compared to zero in 2024) and continued M&A activity, signaling that while the "easy money" has dried up, the sector is maturing toward a more sustainable commercial model.
Market Realities and the "Marketing" Pivot
One of the most compelling insights from the SVB report is the evolution of the "pitch." For years, the women’s health narrative was tethered tightly to reproductive health—contraception, maternal care, and fertility. While these areas remain vital, they have historically been viewed by traditional biotech investors as niche or difficult to monetize.
"Women’s health is a category that, to some extent, has been out of favor with traditional biotech investors," notes Douglas Tsao, a senior analyst and managing director at H.C. Wainwright. This skepticism is compounded by the commercial struggles of recent launches. For example, Astellas Pharma’s Veozah, a non-hormonal treatment for menopause, faced significant hurdles regarding reimbursement and consumer demand, reaching only $300 million in sales last year—a figure that, while notable, failed to meet the aggressive growth expectations of the venture capital community.
The New Strategy: Universal Health
In response to this, the "marketing" of these startups is changing. Founders are no longer framing their products exclusively as "women’s health" solutions. Instead, they are positioning their technologies to address systemic conditions—such as obesity, cardiovascular disease, and depression—that affect both men and women but manifest differently or disproportionately in the female population.
As Megan Scheffel, head of life sciences and healthcare for SVB, aptly put it: "People don’t come out and say ‘I’m serving women’ because they’re not only serving women; they’re serving men and women. It’s like a marketing issue more than it is anything else." By expanding the Total Addressable Market (TAM), these companies are attempting to lower the barrier for traditional, non-niche investors to enter the cap table.
Competitive Pressures: The AI Shadow
While women’s health startups are grappling with their own identity crisis, they are also fighting for attention in a room dominated by the AI boom. Payal Divakaran of .406 Ventures points out that AI-centric startups are currently "sucking up a lot of the air in the room."
The biopharmaceutical space is witnessing a massive migration of capital toward AI-driven drug discovery. While these AI tools hold immense potential for the entire healthcare sector, women’s health companies have been slower to capitalize on the integration of these technologies. This creates a dangerous feedback loop: as investors flock to the most "AI-forward" companies, those who have not yet digitized their data or integrated machine learning models are finding themselves at a disadvantage, regardless of the clinical efficacy of their underlying research.
Official Responses and Industry Outlook
The industry consensus, according to experts like Scheffel, is that this period of contraction is not a death knell but a necessary "recalibration." The days of securing massive funding rounds based on a slide deck and a mission statement are over.
"While initial capital remains available, the baseline to secure it has shifted dramatically," Scheffel explained. "Progress that used to be the province of Series A is now required to raise a Seed round."
This new mandate for "tangible early traction" has forced a more rigorous approach to product development. Startups are now being measured against strict KPIs (Key Performance Indicators) that track clinical progress, user adoption, and, crucially, reimbursement viability.
Is AI the Missing Link?
Despite the current disparity in AI investment, there is a silver lining. Many women’s health companies have spent years building proprietary, longitudinal datasets regarding pregnancy, menopause, and hormonal health. This data is increasingly viewed as a "gold mine" for developers of AI-driven diagnostic and therapeutic tools.
If these companies can leverage their unique data sets to train specialized AI models, they could transform from "niche" players into essential partners for big pharma and tech giants. As Scheffel suggests, "There’s a pretty big opportunity for change" if these startups can effectively bridge the gap between their unique clinical insights and the computational power of modern AI.
Implications: The Path Forward
What does this mean for the future of women’s health? The outlook is nuanced. The era of easy, broad-based venture funding is behind us, but the infrastructure for a more durable, commercialized sector is being built.
- M&A as a Validation Mechanism: The fact that 18 women’s health companies were acquired in 2025, despite the funding dip, proves that the underlying technology is sound. Larger pharmaceutical players are still hungry for innovation, provided that the risk has been mitigated by the startup.
- The Rise of "Low-Barrier" Entry: As Douglas Tsao observed, the immediate future of the sector may lie in diagnostics and testing services. These models offer a faster route to revenue than complex drug development, providing the cash flow necessary to fund long-term R&D.
- The Unicorn Trajectory: The emergence of unicorns like Flo Health, Midi Health, and Maven suggests that investors are willing to back companies that achieve scale. These companies have successfully moved beyond the "niche" branding to become household names, proving that the demand exists if the product-market fit is precise.
Conclusion: A Maturity Milestone
The women’s health sector is currently enduring the painful but necessary growing pains of a maturing market. The "reset" described by SVB is effectively filtering out companies that lack commercial substance while rewarding those that can prove their value in a crowded, competitive, and capital-sensitive environment.
For entrepreneurs, the message is clear: the era of the mission-driven narrative is over, and the era of the metrics-driven reality has begun. While the path to funding is steeper than it was in 2024, the opportunities for those who can successfully pivot, integrate AI, and address broad-scale health issues with gender-specific precision are greater than ever. The sector is no longer just "the future of healthcare"—it is becoming a vital, integrated component of the global medical economy, forced to grow up, get lean, and prove its worth.
About the Author
